“In August 2023, as part of the Inflation Reduction Act (IRA) of 2022, the company’s oncology product Imbruvica sold in the United States (U.S.) was included on the list of products selected for negotiation by the Centers for Medicare & Medicaid Services. The selection resulted in a significant decrease in the estimated future cash flows for the product and represented a triggering event.”
All entries for: AbbVie
November 6, 2023
AbbVie
Negative Outlook
Chicago, IL
50,001+ employees
50001+ employees
Disease Area: Oncology
Drug Type: Biologic
August 7, 2023
AbbVie
Negative Outlook
Chicago, IL
50,001+ employees
50001+ employees
Disease Area: Oncology
Drug Type: Biologic
May 5, 2023
AbbVie
Negative Outlook
Chicago, IL
50,001+ employees
50001+ employees
Disease Area: Oncology
Drug Type: Biologic
October 28, 2022
AbbVie
Negative Outlook
Chicago, IL
50,001+ employees
50001+ employees
Andrew Baum of Citigroup asked how ABBV anticipates pricing pressure assuming CMS selects Imbruvica for the Drug Price Negotiation Program and whether they expect it before 2026 due to expected contracting on formulary placement.
Disease Area: Oncology
Drug Type: Biologic
